放射性标记PD-L1靶向纳米抗体在可切除非小细胞肺癌免疫联合化疗预测与评估中的效能
这项前瞻性研究纳入50例可切除NSCLC患者,基线行68Ga-THP-APN09 PET/CT和18F-FDG PET/CT,36例随访复查68Ga-THP-APN09 PET/CT,比较各显像对主要病理缓解(MPR)的预测效能。基线68Ga-THP-APN09 PET/CT的SUVmax在MPR与非MPR组间有统计学差异,AUC为0.88(95%CI:0.77-0.99);随访68Ga-THP-APN09及18F-FDG PET/CT的SUVmax及变化率均显示良好预测效能。
要点
- 基线68Ga-THP-APN09 PET/CT的SUVmax在PD-L1高阳性表达患者中显著高于低阳性和阴性表达者(P=0.001)。
- 41例手术患者中27例达到MPR、14例未达到,基线68Ga-THP-APN09 PET/CT SUVmax鉴别MPR的AUC为0.88(95%CI:0.77-0.99)。
- 随访68Ga-THP-APN09 PET/CT可提示免疫治疗相关甲状腺炎的可能。
核心结论
- 基线68Ga-THP-APN09 PET/CT单独即可预测疗效并辅助可切除NSCLC免疫联合化疗的患者筛选。
- 随访68Ga-THP-APN09 PET/CT及其变化率可辅助治疗评估。
- 随访68Ga-THP-APN09 PET/CT可用于监测治疗期间的免疫治疗相关甲状腺炎。
研究设计与样本
- 前瞻性研究,纳入50例可切除非小细胞肺癌(NSCLC)患者,基线行68Ga-THP-APN09 PET/CT和18F-FDG PET/CT,36例患者随访复查68Ga-THP-APN09 PET/CT。
- 患者接受2-4周期特瑞普利单抗联合化疗,在R0切除可行时行手术。
- 记录术后标本的主要病理缓解(MPR)状态及联合治疗后的不良反应。
- 分析PD-L1表达与基线68Ga-THP-APN09 PET/CT摄取的相关性,并比较基线和随访68Ga-THP-APN09 PET/CT及18F-FDG PET/CT对MPR的预测和评估效能。
主要发现
- 基线68Ga-THP-APN09 PET/CT的SUVmax在PD-L1高阳性表达患者中显著高于低阳性和阴性表达者(P=0.001)。
- 按18F-FDG PET/CT评估的应答组,其基线68Ga-THP-APN09 PET/CT的SUVmax显著高于无应答组(3.4 vs. 2.4,P<0.001)。
- 41例手术患者中27例达到MPR、14例未达到,基线68Ga-THP-APN09 PET/CT的SUVmax在MPR与非MPR组间有统计学差异,鉴别MPR的AUC为0.88(95%CI:0.77-0.99)。
- 基线18F-FDG PET/CT的SUVmax未显示显著预测效能,AUC为0.68(95%CI:0.50-0.86,P=0.076)。
- 随访68Ga-THP-APN09 PET/CT、随访18F-FDG PET/CT及其变化率(ΔSUVmax%)鉴别MPR均显示良好预测效能,AUC分别为0.81(0.64-0.98)、0.91(0.82-1.00)、0.93(0.84-1.00)和0.96(0.89-1.00)。
关键数值与推荐
- 基线68Ga-THP-APN09 PET/CT的SUVmax在PD-L1高阳性表达患者中显著高于低阳性和阴性表达者(P=0.001)。
- 基线68Ga-THP-APN09 PET/CT的SUVmax在18F-FDG PET/CT评估的应答组显著高于无应答组(3.4 vs. 2.4,P<0.001)。
- 基线68Ga-THP-APN09 PET/CT的SUVmax鉴别MPR的AUC为0.88(95%CI:0.77-0.99)。
- 基线18F-FDG PET/CT的SUVmax鉴别MPR的AUC为0.68(95%CI:0.50-0.86,P=0.076)。
- 随访68Ga-THP-APN09 PET/CT、随访18F-FDG PET/CT及其ΔSUVmax%鉴别MPR的AUC分别为0.81(0.64-0.98)、0.91(0.82-1.00)、0.93(0.84-1.00)和0.96(0.89-1.00)。
临床怎么用
- 基线68Ga-THP-APN09 PET/CT单独即可预测疗效并辅助可切除NSCLC免疫联合化疗的患者筛选。
- 随访68Ga-THP-APN09 PET/CT及其变化率可辅助治疗评估。
- 随访68Ga-THP-APN09 PET/CT可用于监测治疗期间的免疫治疗相关甲状腺炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to assess the predictive and evaluative value of PD-L1 targeted 68Ga-THP-APN09 PET/CT in the neoadjuvant immunotherapy combined with chemotherapy for resectable non-small cell lung cancer (NSCLC), and to explore its potential in indicating immunotherapy-related adverse effects (irAEs). METHODS: Fifty patients with resectable NSCLC enrolled in this prospective study underwent baseline 68Ga-THP-APN09 PET/CT and 18F-FDG PET/CT, with follow-up 18F-FDG PET/CT conducted, additionally, 36 patients received follow-up 68Ga-THP-APN09 PET/CT. Surgery was performed following 2-4 cycles of toripalimab combined with chemotherapy if R0 resection was feasible. The major pathologic response (MPR) state of the post-operative specimen and the adverse effects following combined therapy were documented. The correlation between PD-L1 expression and baseline 68Ga-THP-APN09 PET/CT uptake was determined. The predictive and evaluative efficacies of baseline and follow-up 68Ga-THP-APN09 PET/CT, along with 18F-FDG PET/CT, in determining MPR, were compared. RESULTS: The SUVmax values of baseline 68Ga-THP-APN09 PET/CT were significantly higher in patients exhibiting high-positive PD-L1 expression compared to those with low-positive and negative expression (P = 0.001). And the SUVmax values of baseline 68Ga-THP-APN09 PET/CT in the response group, as determined by 18F-FDG PET/CT evaluation, were significantly higher than those in the non-response group (3.4 vs. 2.4, P < 0.001). Totally, 41 patients underwent surgery, of which 27 achieved MPR, while 14 did not. The SUVmax in baseline 68Ga-THP-APN09 PET/CT demonstrated statistical significance between the MPR and non-MPR groups, with area under the ROC curve (AUC) of 0.88 (95%CI: 0.77-0.99) in identifying MPR. However, the SUVmax in baseline 18F-FDG PET/CT failed to demonstrated significant predictive power, with AUC values of 0.68 (95%CI: 0.50-0.86, P = 0.076). While the SUVmax in follow-up 68Ga-THP-APN09 and 18F-FDG PET/CT, along with their change rate (ΔSUVmax%), demonstrated good predictive efficacy in identifying MPR, with AUC values of 0.81 (0.64-0.98), 0.91 (0.82-1.00), 0.93 (0.84-1.00), and 0.96 (0.89-1.00), respectively. Furthermore, the follow-up 68Ga-THP-APN09 PET/CT could remarkedly indicate the potential for thyroiditis. CONCLUSION: Baseline 68Ga-THP-APN09 PET/CT alone could predict efficacy and assist in patient screening for immunotherapy combined chemotherapy in resectable NSCLC, and the follow-up 68Ga-THP-APN09 PET/CT and their change rates could aid in therapy evaluation. Additionally, follow-up 68Ga-THP-APN09 PET/CT could be utilized to monitor the immunotherapy-related thyroiditis during the therapy. TRIAL REGISTRATION: NCT05156515, registered 8 December 2021, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000BMSI%26;selectaction=Edit%26;uid=U000503E%26;ts=2%26;cx=zeghuw .
引用
- Zhou X, Yan S, Ma X, et al. Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39912938. doi:10.1007/s00259-025-07115-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。